XOMA Corp. regulatory update

XOMA (Berkeley, Calif.) will receive on May 16 U.S. Patent No. 5,416,207 containing composition of matter claims for DNA encoding XOMA's recombinant gelonin (rGelonin), a ribosome-inactivating enzyme, and gelonin analogs.

XOMA is developing Genimune - a targeted immunofusion product consisting of a humanized antibody portion and rGelonin - to kill human T cells involved in autoimmune diseases and immune cell cancers. ...